Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.
- Trial name
- D2570-202 (NCT07035041)
- Testing
- D-2570
- Where
- China
- Volunteers
- 120 people
- Sponsor
- InventisBio Co., Ltd
Ulcerative Colitis
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response…
- Trial name
- NCT02426372
- Testing
- QBECO SSI
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Qu Biologics Inc.
Ulcerative Colitis, Large Intestine
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
The participation in this clinical study will last approximately 21 weeks with a 1 week screening period and a 12 weeks treatment duration.
- Conditions
- Ulcerative Colitis, Large Intestine, Diarrhea, Abdominal Pain
- Trial name
- NCT01011322
- Testing
- LT-02
- Where
- 26 sites in Germany, Lithuania and 1 more
- Volunteers
- 156 people
- Sponsor
- Lipid Therapeutics GmbH
Ulcerative Colitis
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis
This study will evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis.
- Trial name
- NCT00033943
- Testing
- deligoparin
- Where
- 33 sites in United States
- Volunteers
- 270 people
- Sponsor
- Incara Pharmaceuticals
Colitis, Ulcerative
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
This study will involve the use of a new compound, SB-656933. Accumulation of inflammatory white blood cells (mostly polymorphonuclear neutrophils)in the gut (colon) may be contributing to the pathology of ulcerative colitis.
- Trial name
- NCT00748410
- Testing
- SB-656933
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease, Ulcerative Colitis
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD).
- Conditions
- Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
- Trial name
- DEVELOP (NCT00606346)
- Testing
- Anti TNF therapy including infliximab, No Biologics
- Where
- 62 sites in United States, Canada
- Volunteers
- 4,970 people
- Sponsor
- Janssen Biotech, Inc.
Ulcerative Colitis (Disorder), Crohn Disease
Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA
This is a multicenter, open-label, randomized two-arm interventional nutritional study evaluating the effects of partial enteral nutrition (LH VIOLA) in patients with Inflammatory Bowel Disease (IBD) at risk of malnutrition.
- Conditions
- Ulcerative Colitis (Disorder), Crohn Disease, Malnutrition or Risk of Malnutrition, IBD
- Trial name
- SIMBA (NCT07433946)
- Testing
- LH VIOLA Supplementation
- Where
- 4 sites in Italy
- Volunteers
- 146 people
- Sponsor
- Lionhealth Srl Società Benefit
Ulcerative Colitis
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
The study has been designed as a randomised, parallel-group, double-blind, 2 arm study of the comparative efficacy, safety and immunogenicity of AVT16 and Entyvio in male and female subjects with moderate to severe active…
- Trial name
- NCT06570772
- Testing
- AVT16, Vedolizumab
- Where
- 100 sites in Argentina, Bulgaria and 9 more
- Volunteers
- 301 people
- Sponsor
- Alvotech Swiss AG
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
The main aim of this study is to check the disease activity in people with moderate to severe ulcerative colitis and Crohn's disease.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- RISE-MX (NCT04873700)
- Where
- 12 sites in Mexico
- Volunteers
- 335 people
- Sponsor
- Takeda
Ulcerative Colitis (UC)
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis…
- Trial name
- U-Accomplish (NCT03653026)
- Testing
- Upadacitinib
- Where
- 379 sites in United States, Argentina and 42 more
- Volunteers
- 522 people
- Sponsor
- AbbVie
Ulcerative Colitis in Remission
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission…
- Trial name
- NCT01257399
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
The purpose of this study is to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) treated with Guselkumab in a real-world setting, and to assess the clinical effectiveness (how well the treatment…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
- Trial name
- GORGEOUS (NCT07102368)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Janssen-Cilag G.m.b.H
Ulcerative Colitis
A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice
The purpose of this study is to describe the initial response to ustekinumab induction treatment for ulcerative colitis (UC) in Japan.
- Trial name
- NCT04963725
- Testing
- Ustekinumab
- Where
- 23 sites in Japan
- Volunteers
- 137 people
- Sponsor
- Janssen Pharmaceutical K.K.
Crohn's Disease, Ulcerative Colitis
To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
An observational, prospective cohort study to evaluate the safety and efficacy of Remsima™ in patients with Crohn's disease (CD) or Ulcerative Colitis (UC)
- Trial name
- NCT02326155
- Volunteers
- 470 people
- Sponsor
- Celltrion
Ulcerative Colitis, Crohn's Disease
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time.
- Trial name
- NCT06405087
- Testing
- Vedolizumab SC, No Intervention
- Where
- 47 sites in United States, Belgium and 12 more
- Volunteers
- 70 people
- Sponsor
- Takeda
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06598943
- Testing
- Eltrekibart, Mirikizumab
- Where
- 207 sites in United States, Argentina and 19 more
- Volunteers
- 143 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis
A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days.
- Trial name
- NCT04353791
- Testing
- OST-122
- Where
- 16 sites in Spain, Ukraine
- Volunteers
- 32 people
- Sponsor
- Oncostellae S.L
Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
This phase 2 study is being conducted to evaluate the efficacy, safety and pharmacokinetics of SHR-1139 in patients with moderate to severe active ulcerative colitis.
- Trial name
- NCT07232576
- Testing
- SHR-1139 intravenous injection.
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis
Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.
- Trial name
- NCT03923478
- Testing
- ABI-M201
- Where
- 11 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Assembly Biosciences
Crohn's Disease, Ulcerative Colitis
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract.
- Trial name
- TATOO (NCT07421258)
- Where
- 5 sites in China, France and 1 more
- Volunteers
- 1,638 people
- Sponsor
- AbbVie